AI assistant
DEXCOM INC — Director's Dealing 2018
Mar 12, 2018
30198_dirs_2018-03-12_79ce320e-cf64-49c2-8a18-ec2fcd4dad2a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2018-03-08
Reporting Person: Abbey Donald (EVP, Quality & Regulatory Afrs)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-03-08 | Common Stock | A | 38502 | $0.001 | Acquired | 113228 | Direct |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.
F2: Included in this number are 93,508 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 36,666 of which were granted on May 31, 2016 and shall vest through May 31, 2019.